<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02732184</url>
  </required_header>
  <id_info>
    <org_study_id>CAEB1102-100C</org_study_id>
    <nct_id>NCT02732184</nct_id>
  </id_info>
  <brief_title>A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS</brief_title>
  <official_title>A Phase 1 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aeglea Biotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aeglea Biotherapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first study of the safety of increasing dose levels of AEB1102 in patients with
      Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. The study will
      also evaluate the amounts of AEB1102 in blood, the effects of AEB1102 on blood amino acid
      levels and the antitumor effects of AEB1102.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose and Recommended Phase 2 Dose</measure>
    <time_frame>4 weeks</time_frame>
    <description>The dose level at which no more than 1/6 patients experiences dose-limiting toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile (changes in physical exam, laboratory measures, reported adverse events)</measure>
    <time_frame>4 Weeks</time_frame>
    <description>changes in physical exam, laboratory measures, reported adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>AEB1102 (Co-ArgI-PEG) administered via IV weekly.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Co-ArgI-PEG modified human arginase I</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Co-ArgI-PEG modified human arginase I</intervention_name>
    <arm_group_label>AEB1102 (Co-ArgI-PEG) administered via IV weekly.</arm_group_label>
    <other_name>AEB1102</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide informed consent

          -  Age 18 and older

          -  Diagnosis of AML or MDS according to the WHO criteria

          -  AML relapsed or refractory to at least one attempt at induction or subjects not
             candidates for aggressive induction regimens

          -  MDS refractory to treatment with HMA therapy or with recurrence or progression of MDS
             following a response to an HMA

          -  Has adequate organ function: AST and ALT &lt; 3X the ULN, serum bilirubin &lt; 2X the ULN,
             serum creatinine of &lt; 2 mg/dL, or a calculated creatinine clearance of &gt; 50 mL/minute

          -  ECOG Performance Score of 0 -2

          -  Recovered from the effects of any prior systemic therapy, radiotherapy or surgery

          -  Willing to use physician approved birth control method

        Exclusion Criteria:

          -  Current CNS Leukemia

          -  Acute promyelocytic leukemia or AML with a t(15;17) (q22;q12) cytogenetic abnormality
             or Bcr/Abl positive leukemia

          -  &lt; 60 days from ASCT; has chronic graft-versus host disease (GVHD) or requires
             continued treatment with systemic immunosuppressive agents

          -  Uncontrolled infection

          -  Known HIV, hepatitis B or hepatitis C.

          -  Other active malignancy that requires therapy

          -  If female, is lactating or breast feeding

          -  Hypersensitivity to PEG or other component of AEB1102 (Co-ArgI-PEG)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Joffrion</last_name>
    <role>Study Director</role>
    <affiliation>Aeglea BioTherapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Medical School</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2016</study_first_submitted>
  <study_first_submitted_qc>April 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2016</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

